You can buy or sell Cue Biopharma and other stocks, options, ETFs, and crypto commission-free!
Cue Biopharma, Inc. Common Stock, also called Cue Biopharma, is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Read More Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 9
Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference
Overview and Update on the Immuno-STAT Platform for Selective Targeting of Tumor-specific T cells CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today Anish Suri, Ph.D., Senior Vice President and Chief Scientific Officer will participate in a panel discussion en...
Yahoo FinanceApr 29